HES is derived from waxy maize starch and can be metabolised by the body’s enzymes.
Fresenius Kabi provided Boehringer with its HESylation Technology to manufacture HES conjugated to a therapeutic protein.
HESylation Technology allows a targeted modification of drugs and their characteristics by site-specific coupling to HES molecules.
HES-coupling enables the modification of key pharmacological parameters such as absorption, metabolisation, half-life, water solubility and safety.
Boehringer Ingelheim and Fresenius Kabi will actively evaluate further opportunities to extend the collaboration and to apply HESylation Technology, respectively.